Pregled bibliografske jedinice broj: 929248
MSCT imaging of hepatocelullar carcinoma
MSCT imaging of hepatocelullar carcinoma // Poster ECR 2018
Beč: ECR, 2018. C-2412, 9 doi:0.1594/ecr2018/C-2412 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 929248 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
MSCT imaging of hepatocelullar carcinoma
Autori
Ištvanović, Lucija ; Kavur, Lovro ; Vidjak, Vinko ; Matijević, Filip ; Matković, Andro ; Drinković, Martin
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Poster ECR 2018
/ - Beč : ECR, 2018
Skup
European Congress of Radiology (ECR 2018)
Mjesto i datum
Beč, Austrija, 28.02.2018. - 04.03.2018
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
hepatocellular carcinoma ; chronic liver disease ; multislice CT
Sažetak
Background HCC is the most common primary malignancy of the liver in adults. It occurs predominantly in patients with underlying chronic liver disease and cirrhosis as a consequence of viral infection (HBV, HCV), or exposure to toxins such as alcohol or aflatoxin. The molecular and cellular mechanisms underlying hepatocarcinogenesis- the transformation od nonmalignant cell into HCC, is not yet fully elucidated. Chronic inflammation plays a crucial role by causing repeated cycles of cell injury, death and regeneration which increases the risk of aberrant cell signalling, epigenetic changes, mutations and accumulation of genetic damage. Findings and procedure details MSCT and MR imaging with extracellular contrast agents are first-line modalities for diagnosis and staging of HCC. Advantages of CT are availability, speed and needs less expertise to perform and interpret images, while disadvantages are radiation exposure and relatively low soft-tissue contrast, in comparison with MR imaging. MR imaging with hepatobiliary agents (gadoxetate-sodium and gadobenate dimeglumine) tends to become a leading method for diagnosing and staging HCC since it appears. Conclusion Currently, all major clinical practice guidelines endorse MSCT and MR imaging with extracellular contrast agents as first-line modalities for diagnosis and staging of HCC. These examinations should include late hepatic arterial, portal venous and delayed phase acquisitions. Precontrast images are needed in MR imaging, while in CT imaging often are omitted. Some studies have shown a slightly better performance of dynamic MR imaging then multiphasic CT, but differences are small.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinička bolnica "Merkur",
Medicinski fakultet, Zagreb,
Sveučilište u Zagrebu